NeoGenomics Stock Price and Value Analysis

Should you buy NeoGenomics stock? (NasdaqCM:NEO). Let's see how it does in our automated value investing analysis system.

  • This company is less known than others.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the NEO Numbers

NEO Price
(NeoGenomics stock price per share)
[?] PE Ratio versus Sector 1307% higher than other Healthcare stocks
[?] PE Ratio versus Industry 392% higher than other Diagnostics & Research stocks
[?] Free Cash Flow Jitter 189%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,386,529 shares shorted. With 121,208,127 shares available for purchase and an average trading volume over the past 10 trading days of 1,148,670, it would take at least 4.689 days for all of the short holders to cover their shorts.

Is NeoGenomics Stock on Sale?

Based on our analysis, we believe that you should not buy NeoGenomics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NEO Stock?

Does NeoGenomics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.